Prostate specific antigen density. Is there a role for this parameter when screening for prostate cancer?

Area of Science:

• Urology
• Oncology
• Diagnostic Imaging

Background:

• Elevated prostate-specific antigen (PSA) levels can indicate prostate cancer (PCa), but lack specificity.
• Intermediate PSA values (4-10 ng/ml) in men with normal digital rectal exams (DRE) present a diagnostic challenge.
• Prostate-specific antigen density (PSAD) has been proposed to improve diagnostic accuracy.

Purpose of the Study:

• To evaluate the routine use of PSAD to enhance PSA specificity in men with normal DRE and intermediate PSA values.
• To determine if PSAD can reliably differentiate between prostate cancer and benign conditions in the specified patient cohort.

Main Methods:

• Retrospective analysis of 235 men from a PCa screening program.
• Inclusion criteria: PSA 4-10 ng/ml, normal DRE, available transrectal ultrasound (TRUS)-guided biopsy.
• Multivariate analysis was employed to assess PSAD's predictive value.

Main Results:

• Multivariate analysis did not demonstrate significantly higher PSAD values in men with confirmed PCa.
• A PSAD cutoff of 0.07 ng/ml/cc showed less than 95% sensitivity, deemed unacceptable.
• A higher PSAD cutoff of 0.15 ng/ml/cc resulted in missing 30.6% of PCa cases.

Conclusions:

• The routine use of PSAD is not recommended for enhancing PSA specificity in men with normal DRE and intermediate PSA values.
• PSAD demonstrated insufficient sensitivity and accuracy for reliable PCa detection in this clinical context.
• Further research may be needed to identify more effective biomarkers or strategies for PCa diagnosis in this patient group.